Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CBP-201

Monoclonal antibody · developed by Connect Biopharm LLC

Phase 3 Most advanced trial (none active)

CNTB Developer

2 Registered trials

What is CBP-201?

CBP-201 is a drug given by subcutaneous injection. It is studied in atopic dermatitis and in healthy adult subjects.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Therapy area: Dermatology, Immunology
Developer: Connect Biopharm LLC (CNTB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05614817	Phase 3	Atopic Dermatitis	Withdrawn	CNTB
NCT05917782	Phase 1	Healthy Adult Subjects	Completed	CNTB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic DermatitisHealthy Adult Subjects

More from Connect Biopharm LLC

CBP-174 Phase 1 CBP-307 Phase 2 Rademikibart Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CNTB page.

Follow CNTB, the company behind CBP-201

See CNTB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CNTB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z